Oruka Therapeutics
ORKA
12 hedge funds and large institutions have $1.13M invested in Oruka Therapeutics in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
18% more capital invested
Capital invested by funds: $958K → $1.13M (+$175K)
0.01% more ownership
Funds ownership: 0.06% → 0.07% (+0.01%)
20% less funds holding
Funds holding: 15 → 12 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$150K |
| 2 |
VF
Virtu Financial
New York
|
+$39.5K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$21.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$11K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.1K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.45K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
1
Tekla Capital Management
Boston,
Massachusetts
| $454K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $375K | +$150K | +1,163 | +60% |
|
|
3
Acadian Asset Management
Boston,
Massachusetts
| $76K | +$21.4K | +166 | +36% |
|
|
ACP
4
Aveo Capital Partners
Englewood,
Colorado
| $58K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $57K | +$39.5K | +306 | +194% |
|
|
PAM
6
Panagora Asset Management
Boston,
Massachusetts
| $48K | -$2.45K | -19 | -5% |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $29K | +$7.36K | +57 | +31% |
|
8
Geode Capital Management
Boston,
Massachusetts
| $27K | – | – | – |
|
9
Northern Trust
Chicago,
Illinois
| $8K | – | – | – |
|
10
Morgan Stanley
New York
| $1K | – | – | – |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$26K | -221 | Closed |
|
|
CS
12
Credit Suisse
Zurich,
Switzerland
| – | -$11K | -93 | Closed |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$3.1K | -24 | Closed |
|
ORKA Hedge Fund Activity: Q3 2018 in Review
12 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2018, worth a combined $1.13M — up 18% from $958K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ORKA and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $150K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $26K sold.
- 12 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2018, down from 15 in Q2 2018.
- Funds reported $1.13M of Oruka Therapeutics stock for Q3 2018, up 18% quarter-over-quarter.
- 0 funds opened new Oruka Therapeutics positions in Q3 2018 and 3 closed out, a net change of -3 holders.
- The largest Oruka Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $150K added.
- The largest Oruka Therapeutics seller in Q3 2018 was Susquehanna International Group, an estimated $26K sold.
Based on aggregated 13F filings for Q3 2018.